Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.